fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Annual breast cancer screening beginning at 40 saves lives

Written by | 23 Feb 2024

Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks, according to a… read more.

BLA resubmitted to FDA for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma – Citius Pharmaceuticals

Written by | 22 Feb 2024

The biologics license application (BLA) for the interleukin (IL)-2–based immunotherapy denileukin diftitox (Lymphir) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least 1 prior… read more.

New method could detect early ovarian cancer from urine samples

Written by | 15 Feb 2024

New research by Joseph Reiner and colleagues at Virginia Commonwealth University shows promise for a urine-based test for ovarian cancer. Reiner will present their research at the 68th Biophysical… read more.

FDA acceptance of U.S. and EU regulatory filings for neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo in resectable non-small cell lung cancer – BMS

Written by | 12 Feb 2024

Bristol Myers Squibb announced two regulatory acceptances for applications for; i. neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and ii. adjuvant Opdivo for the perioperative treatment of… read more.

Regulatory applications accepted in the U.S. and Japan for Breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and relapsed or refractory mantle cell lymphoma – BMS

Written by | 9 Feb 2024

Bristol Myers Squibb announced three regulatory acceptances from the FDA and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel) In the U.S., the FDA… read more.

FDA acceptance of the PMA application for TTFields therapy for non-small cell lung cancer – Novocure

Written by | 1 Feb 2024

Novocure announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of… read more.

Analyses of Yescarta CAR T-cell therapy support curative potential in patients with non-Hodgkin lymphomas – Kite/Gilead Sciences

Written by | 30 Dec 2023

Kite, a Gilead Company announced data from follow-up analyses of three studies of Yescarta (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types… read more.

Study: Colon cancer screenings are more effective than previously understood

Written by | 23 Dec 2023

Screening for colon cancer reduces cancer rates by substantially more than previous analyses of randomized trials suggest, according to a study co-authored by an MIT economist that takes… read more.

Ultrafast laser technology could offer improved cancer treatment

Written by | 20 Dec 2023

Ultrafast laser technology continues to surprise. While research in this field may seem rather abstract at first glance, it very often leads to concrete applications. This is particularly… read more.

Some breast cancer survivors may safely de-escalate mammography three years after surgery

Written by | 11 Dec 2023

Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography, according… read more.

Abecma is the first CAR T approved for use in earlier lines of therapy for patients with relapsed or refractory multiple myeloma in Japan – BMS

Written by | 11 Dec 2023

Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.

Regular screening mammograms significantly reduce breast cancer deaths

Written by | 3 Dec 2023

Breast cancer mortality is significantly reduced when women regularly attend screening mammograms, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA)…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.